Research Grade Lintuzumab
Lintuzumabisahumanizedmonoclonalantibody, HuM195, thattargetsthecellsurfaceantigenCD33thatisexpressedonthevastmajorityofacutemyeloidleukemia (AML) cells.[225Ac]Ac-lintuzumabclinicaltrialswerediscussedindetailinreference.LintuzumabisunderinvestigationinclinicaltrialNCT00016159 (ChemotherapyPlusMonoclonalAntibodyinTreatingPatientsWithAcutePromyelocyticLeukemia) .
Product Specifications
Product Name Alternative
225Ac-lintuzumab, HuM195, SGN-33, SMARTM195, HuM195, CAS:166089-32-3
Expression System
Mammalian Cells
Host
Humanized
Target
MyeloidcellsurfaceantigenCD33, Sialicacid-bindingIg-likelectin3, Siglec-3, CD33, gp67, SIGLEC3
Clonality
Monoclonal
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Purification
Protein A/G purified from cell culture supernatant.
Concentration
1.39mg/ml
Endotoxin
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Form
Liquid
Buffer
0.01M PBS, pH7.4.
Storage Conditions
Notes
For research use only. Not suitable for clinical or therapeutic use.
Buffer pH
0.01M PBS, pH7.4.
Species
Human
Isotype
IgG1-kappa
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog